Predictors of Cardiovascular Morbidities in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia
Authors' conclusion
Cardiometabolic morbidities are prevalent among adults with 21OHD. Hypertension, age, and GC exposure are the main predictive factors of established CVDs in our cohort.
Study context
- Population
- Adults aged 18 to 70 years with confirmed 21-hydroxylase deficiency CAH, ≥1 clinical visit at the University of Michigan; median age 35 years (IQR 28.25–46 y)
- Participants
- 254 adults
- Outcome
- Prevalence of CVDs (International Classification of Diseases (ICD) codes) and clinical factors and biomarkers associated with CVDs
Methodological details10-year, single-centre
- 10-year
- Single-centre
Main finding
As reported in the abstract
- Prevalence of cardiovascular diseases (CVDs), entire cohort
- 7.5%
- Prevalence of CVDs, patients older than 60 years
- 25%
- Increasing age and prevalent CVDs, adjusted OR
- 1.05 (1.01-1.09) (95% CI)
- Hypertension and prevalent CVDs, OR
- 4.27 (1.41-12.92) (95% CI)
- Higher glucocorticoid (GC) doses and prevalent CVDs, OR
- 1.51 (1.11-2.06) (95% CI)
- Higher plasma renin activity and CVDs, OR
- 1.07 (1.01-1.15) (95% CI)
Observational data: associations, not effects.
Original publication
Predictors of Cardiovascular Morbidities in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. Published 25 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →